gen1044 is an immunoglobulin g1 bispecific antibody targeting cd3 and 5t4.
Locally Advanced or Metastatic Solid Tumor(s)
Genmabmonoclonal_antibodyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
276 Active assets in the Locally Advanced or Metastatic Solid Tumor(s) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM I-Mab Biopharma US Limited | Phase 3 | BB |
Irinotecan Incyte Corporation | Phase 3 | BB |
FILGRASTIM Mayo Clinic | Phase 3 | BB |
Pembrolizumab InSilico Medicine Hong Kong Limited | Phase 2/3 | BB |
Cyclophosphamide InSilico Medicine Hong Kong Limited | Phase 2/3 | BB |
View all 50 →
Same molecule, other indications
gen1044 is an immunoglobulin g1 bispecific antibody targeting cd3 and 5t4. is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →